Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felzartamab in Lupus Nephritis
NCT06064929Phase 1Completed
- Sponsor
- Biogen
- Start
- Nov 2023
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of felzartamab in lupus nephritis (LN), sponsored by Biogen. Primary endpoint: Number of Participants with Adverse Events at 104 weeks. Started Nov 2023; status: completed.
02
Drugs
felzartamab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT06064929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06064929.